In clinical studies, the EPI test has been demonstrated to efficiently discriminate high-grade (Gleason score ≥ 7) from low-grade (Gleason score 6) prostate cancer and benign disease in men ≥ 50 years with equivocal PSA levels (2–10 ng/mL), thereby reducing the number of unnecessary tissue biopsies [142,143]. The gene discussed is KLK3; the disease is prostate cancer.